Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totaling 1,397,189 shares, an increase of 64.8% from the August 15th total of 847,773 shares. Based on an average trading volume of 249,992 shares, the short-interest ratio is presently 5.6 days. Currently, 1.9% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
BRVE has been the topic of a number of recent analyst reports. Stifel Nicolaus initiated coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group started coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 target price for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. Finally, The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $45.25.
Get Our Latest Analysis on BRVE
Braveheart Bio Price Performance
Braveheart Bio (NASDAQ:BRVE – Get Free Report) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). On average, equities analysts anticipate that Braveheart Bio will post -1.48 EPS for the current year.
Insider Activity
In other news, Director Orbimed Advisors Llc acquired 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Erez Chimovits bought 1,940,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 8,751,942 shares of company stock valued at $157,534,956.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Featured Articles
- Five stocks we like better than Braveheart Bio
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
